Top

Published in:

01-06-2008 | Letter

Laparoscopic gastrectomy: advances enable wide clinical application

Authors: T. Liakakos, D. Roukos

Published in: Surgical Endoscopy | Issue 6/2008

Excerpt

The current trend is toward laparoscopic gastrectomy. Although no level 1 randomized evidence or cost-effective analysis exists to show the superiority of laparoscopic gastrectomy over open gastrectomy, the indications and use of laparoscopic gastrectomy in clinical practice have been expanded beyond the carefully selected older patients described in the report by Singh et al. [1] in a recent issue of this journal. A current published report shows the clinical use of laparoscopic gastrectomy for early-stage gastric cancer with a trend also toward locally advanced carcinoma [2] and for carriers of CDH1 mutations to prevent hereditary diffuse gastric cancer (HDGC) syndrome [3, 4]. As laparoscopic gastrectomy currently is being applied in an environment of strong competition within various countries and among specialized institutions worldwide to attract patients, what are the benefits and risks of the laparoscopic approach? …

Singh KK, Rohatgi A, Rybinkina I, McCulloch P, Mudan S (2007) Laparoscopic gastrectomy for gastric cancer: early experience among the elderly. Surg Endosc Epub 2007 Sept 2

Lee JH, Kim YW, Ryu KW et al (2007) A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer patients. Ann Surg Oncol 14(11):3148–3153PubMedCrossRef

Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715PubMedCrossRef

Francis WP, Rodrigues DM, Perez NE, Lonardo F, Weaver D, Webber JD (2007) Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric cancer. JSLS 11:142–147PubMed

Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgascouchell S (1990) A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach: an analysis of early results and long-term survival. J Cancer Res Clin 116:307–313CrossRef

Siewert JR, Bottcher K, Stein HJ, Roder JD (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228:449–461PubMedCrossRef

Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81:59–62PubMedCrossRef

Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11:727–730PubMedCrossRef

Sano T (2007) Tailoring treatments for curable gastric cancer. Br J Surg 94:263–264PubMedCrossRef

10.

Wu CW, Hsiung SA, Lo et al (2006) Nodal dissection for patients with gastric cancer: a randomised trial. Lancet Oncol 7:309–315

11.

Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11:127–129PubMedCrossRef

12.

Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3:115–125PubMedCrossRef

13.

Gervasoni JE Jr, Sbayi S, Cady B (2007) Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol 14(9):2443–2462PubMedCrossRef

14.

Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98–107PubMedCrossRef

15.

Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom, and why. Ann R Coll Surg Engl 80:16–24PubMed

16.

Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7:253–255PubMedCrossRef

17.

Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730PubMedCrossRef

18.

Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221PubMedCrossRef

19.

Shehzad K, Mohiuddin K, Nizami S et al (2007) Current status of minimal access surgery for gastric cancer. Surg Oncol 16:85–98. Epub 2007 Jun 7PubMedCrossRef

20.

Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245:873–879PubMedCrossRef

21.

Chung DC, Yoon SS, Lauwers GY, Patel D (2007) Case records of the Massachusetts General Hospital: Case 22-2007: A woman with a family history of gastric and breast cancer. N Engl J Med 357:283–291PubMedCrossRef

22.

Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6:308–312PubMedCrossRef

23.

Kim JJ, Song KY, Chin HM (2008) Totally laparoscopic gastrectomy with various types of intracorporeal anastomosis using laparoscopic linear staplers: preliminary experience. Surg Endosc 22(2):436–442PubMedCrossRef

24.

Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578–590PubMedCrossRef

25.

Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9:607–609PubMed

26.

Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9:941–943PubMed

27.

Ratouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15(1):21–33CrossRef

28.

Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rationale of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11:1030–1034PubMedCrossRef

29.

Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(15):1555-1556 author reply 1556

30.

Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8(1): 29–39PubMedCrossRef

31.

Liakakos T, Roukos DH (2008). More controversy than ever-challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15(4): 956–960 PubMedCrossRef

32.

Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197 author reply 198

33.

Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141PubMedCrossRef

34.

Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (in press)

Title: Laparoscopic gastrectomy: advances enable wide clinical application
Authors: T. Liakakos
D. Roukos
Publication date: 01-06-2008
Publisher: Springer-Verlag
Published in: Surgical Endoscopy / Issue 6/2008
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-008-9869-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Laparoscopic gastrectomy: advances enable wide clinical application

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2008

News and Notices

Laparoscopic colorectal surgery for neoplasm. A large series by a single surgeon

Patterns of esophageal acid exposure after laparoscopic Heller’s myotomy and Dor’s fundoplication for esophageal achalasia

Presentation and management of Morgagni hernias in adults: a review of 298 cases

Randomized blinded trial comparing the cardiopulmonary effects of NOTES with standard laparoscopy in a porcine survival model

Construct validity testing of a laparoscopic surgery simulator (Lap Mentor®)